Extensive efforts have been made to deplete Tregs and remodel the immunosuppressive microenvironment of tumour tissues, including the use of abemaciclib19,20, an anti-CD25 mAb21 or indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors22,23. Here, IDO1 is linked to neoplasm.